Merck & Company Inc (MRK)vsScinai Immunotherapeutics Ltd (SCNI)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
SCNI
Scinai Immunotherapeutics Ltd
$1.66
-0.60%
HEALTHCARE · Cap: $1.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4476632% more annual revenue ($66.57B vs $1.49M). MRK leads profitability with a 4.8% profit margin vs -174.8%. SCNI trades at a lower P/E of 0.1x. SCNI earns a higher WallStSmart Score of 49/100 (D+).
MRK
Hold36
out of 100
Grade: F
SCNI
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for SCNI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 146.0% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Weak financial health signals
ROE of -102.5% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SCNI
The strongest argument for SCNI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 146.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 2.08 — expect wider price swings.
SCNI is growing revenue faster at 146.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
SCNI scores higher overall (49/100 vs 36/100) and 146.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a comprehensive clinical pipeline that aims to deliver transformative therapies to enhance patient outcomes. With a seasoned leadership team and a strong commitment to rigorous research, the company is poised to capitalize on the increasing demand for advanced immunotherapeutics in the global healthcare sector. Strategic partnerships further augment Scinai's growth potential, positioning it as a significant contender within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?